Julie Khlevner, MD
Overview
I am privileged to have achieved my lifelong goal of becoming a pediatric gastroenterologist, more specifically a pediatric neurogastroenterologist. I have a special interest and expertise in disorders of the gut-brain interaction, including motility disorders, which involve the movement of food through the GI tract, and functional disorders, which involve interactions between the brain and GI tract that affect motility. These conditions can be debilitating and yet they remain challenging to treat effectively.
My team and I evaluate and treat children and adolescents using advanced, state-of-the-art diagnostic and therapeutic techniques with multidisciplinary approach. Some of the conditions we treat are dysphagia, achalasia, gastroesophageal reflux disease, chronic nausea, gastroparesis, irritable bowel syndrome, chronic abdominal pain, severe constipation, fecal incontinence, and anorectal disorders.
We think of our patients and their problems holistically and take pride in developing personal connections with patients and their families. My goal is to deliver compassionate, respectful, evidence-based, and humanistic care to children with gastrointestinal diseases.
I co-direct many multidisciplinary clinics, including the Gastrointestinal Motility Center, Esophageal Atresia Clinic, Aerodigestive Program, and Congenital Diaphragmatic Hernia Program, and I work closely with pediatric surgeons, pulmonologists, cardiologists, ear nose throat (ENT) specialists, psychologists, and language pathologists to provide the most comprehensive care to children with complex GI medical conditions.
I also take great pride in educating medical students, residents, fellows, and other providers. I have mentored several GI fellows who have joined other institutions across the county and are currently working to establish multidisciplinary clinics and expand access to care for functional and motility disorders.
In addition to my clinical and education roles, my team and I conduct multiple clinical research projects focusing on functional and motility disorders. I work on clinical trials which allow our patients to have access to therapeutics that are not otherwise offered to children. This work has led to numerous presentations at national meetings and publications in high impact gastroenterology journals—all with the mission of improving children’s health and advancing the science of gastrointestinal motility and functional gastrointestinal diseases.
Areas of Expertise / Conditions Treated
- Abdominal Pain
- Anal Motility Disorders
- Bowel Problems
- Clinical Research
- Colonoscopy
- Congenital Anorectal Defect
- Constipation
- Diarrhea
- Digestive Disorder
- EGD
- Encopresis
- Endoscopic Feeding Tube Placement
- Endoscopy
- Esophageal Atresia
- Esophageal Disorders
- Esophageal Motility Disorder
- Esophageal Motility Studies
- Esophageal Stricture
- Esophagitis
- Esophagogastroduodenoscopy
- Failure to Thrive
- Feeding Problem In Child
- Feeding Problem In Infant
- Gastric Motility Disorder
- Gastroesophogeal Reflux / GERD
- Gastrointestinal Disorders
- Irritable Bowel Syndrome (IBS)
- Motility Disorder, Esophageal
- Motility disorders of the bowel
- Pediatric Gastrointestinal (GI) Endoscopy
- Pediatric Nutrition
- Rectal Disorders
- Small Bowel Problem
- Swallowing Disorder
- Upper Endoscopy
Academic Appointments
- Associate Professor of Pediatrics at CUMC
Administrative Titles
- Director, Pediatric Gastrointestinal Motility Center
Hospital Affiliations
- NewYork-Presbyterian Morgan Stanley Children's Hospital
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Female
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- Aetna Signature Administrators
- NYP Employee Plan
- NY Signature
- Student Health
Affinity Health Plan
- Medicaid Managed Care
Amerigroup of New Jersey
- New Jersey Services (Medicaid Managed Care)
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- EPO
- HMO
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
Fidelis Care
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
Quality Health Management
- Quality Health Management
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- SelectHealth
- Special Needs
WellCare
- Medicare Managed Care
- New Jersey Services (Medicaid Managed Care)
World Trade Center Health Plan
- World Trade Center Health Plan
Credentials & Experience
Education & Training
- Internship: Jacobi Hospital - Albert Einstein College of Medicine
- Residency: Jacobi Hospital - Albert Einstein College of Medicine
- Fellowship: Stony Brook University Medical Center
Board Certifications
- Pediatrics
- Pediatric Gastroenterology
Honors & Awards
New York SuperDoctors Rising Star
Research
Clinical Trials
NCT02559570 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
NCT02559817 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, A Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) (ie, Fulfill Rome III Criteria for Child/Adolescent IBS and Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation
COMPLETED
NCT02042183 A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
NCT02138136 A Multicentre, Long-term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
For a complete list of publications, please visit PubMed.gov